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INTRODUCTION
The human microbiome is comprised of the bacteria,
archaea, viruses, fungi, and other microeukaryotes that live
on and within the human host. Alterations in the microbiome
are associated with adverse transplant outcomes including
the expected infectious complications following allogeneic
hematopoietic cell transplantation (allo-HCT) in addition to
diseases that are not classically microbe associated. For
example, recent data suggest an association between certain
microbial community structures and mortality, disease relapse,
risk of infection, and graft-versus-host disease (GVHD) [1-3].
Most studies inspecting the role of the microbiome in HCT
patient outcomes, though compelling, are limited in scope:
in general, data have been generated in single-center studies
or preclinical models. Here, we summarize many of the main
findings of the past several decades of research on this topic,
and propose areas of focus for future research that will fa-
cilitate investigating the microbiome and its role in disease
(Table 1).
The Earliest Days of Microbiota Research: Germ-Free Mice
and Patients
Pioneering studies conducted in the early 1970s demon-
strated that mice undergoing allo-HCT in germ-free conditions
experienced less GVHD and had improved survival (Table 2)
[4-16]. Soon thereafter, this observation led to attempts to
reproduce these conditions in patients undergoing HCT
through the use of laminar-airflow isolation rooms, “sterile”
Table 1
Proposed Next Steps for Future Research Investigating the Microbiome-Host Relationship in HCT Patients
Primary Research Gaps and Strategies
1. Multi-institutional prospective studies to improve generalizability of microbiota research findings
2. Multicenter biospecimen and data collection to support collaborative and integrative “multi-omic” approaches to microbiota research
3. Expansion of microbial metagenomic studies in HCT patients beyond bacterial taxonomy
a. Investigation of the role of the virome and mycobiome in HCT outcomes
b. Elucidation of microbial genes and metabolic pathways that impact outcomes, in particular the antibiotic resistome
4. Targeting of specific microbes and/or microbial pathways to determine whether modification of the microbiota can impact microbe-disease
associations
5. Investigation of the role of extraintestinal microbial populations (ie, oral, skin, vaginal, and eye) in the development of acute and chronic GVHD
6. Investigation of microbial-host dynamics associated with the development of chronic GVHD and other non-GVHD outcomes
7. Modification of antibiotic strategies that balance preservation and restoration of the microbiome with appropriate infection prevention and treatment
8. Antibiotic-sparing approaches to infection prevention and treatment; steroid-sparing approaches to GVHD prevention and treatment
9. Incorporation of standardized antibiotic and infection-related data into national transplant databases
10. Understanding the potential for using the microbiome as a biomarker for transplant outcomes and as a guide to interventions
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diets, gut decontamination with oral nonabsorbable antibi-
otics, and skin cleansing (Table 3) [17-29]. Between-study
heterogeneity and the lack of reproducible data supporting
efficacy for GVHD prevention have limited evidence-based
guidance for clinical practice and prophylactic strategies.
However, while many of these previous approaches have
largely been abandoned, broadly-adopted modern-day rec-
ommendations to prevent infectious complications include
antimicrobial prophylaxis, sterilized positive air pressure
rooms, low-microbial diet, and use of barrier precautions (eg,
gloves, face masks, gowns) [30]. Recently, there has been a
resurgence of microbiome research across many disciplines
of medicine spurred by advances in high-throughput meth-
odologies for characterizing the microbiome, which extend
beyond bacterial culture techniques and virus-specific mo-
lecular approaches for detection. Similarly, there has been
rapid growth in the microbiome research as it relates to HCT.
METHODS TO INVESTIGATE THE MICROBIOME
With the advent of high-throughput molecular methods
to study the microbiome, the field has grown significantly in
the past decade. Commonly used methods include 16S ri-
bosomal RNA gene sequencing for bacterial taxonomic
classification, metabolomics, as well as shotgun metagenomic
sequencing and subsequent taxonomic and functional clas-
sification of microbial genes; these methods have been
reviewed in detail elsewhere (Table 4) [31-33]. Each of these
methods provides an orthogonal approach to study the
microbiome from the perspective of answering important
microbiota taxonomic and functional questions, including
“which microbes are there?”; “what do they make?”; “what
genes do they contain?”; and “what is their relative and ab-
solute abundance?” [34]. With the explosion of new molecular
and bioinformatic approaches to study the microbiome, we
anticipate an ever-growing toolkit to characterize potential-
ly clinically relevant features of the microbiome such as
antibiotic resistance, microbial virulence factors, and strain
dynamics. Terms commonly used in microbiome studies and
their definitions are listed in Table 5 [31,35-38].
A precedent has recently been set for the generation of
multifaceted data types (ranging from shotgun metagenomic
sequencing to transcriptomes and epigenomes to metabo-
lite profiling) that facilitate multidimensional and longitudinal
characterization of both the host and the microbiome. Spe-
cifically, projects of the integrative Human Microbiome Project,
the U.S. National Institutes of Health Common Fund’s second
phase Human Microbiome Project, have collected longitu-
dinal samples from 3 cohorts of individuals (comprising
individuals with pregnancy and preterm birth, type 2 dia-
betes, and inflammatory bowel disease) [39,40]. Given these
advances in “multi-omic” data collection, we anticipate that
the next decade of translational research in the microbiome
field as it relates to HCT will extend far beyond simple char-
acterization of community taxonomic structures within the
microbiome. For example, advances in immunophenotyping
and short-term, in vitro propagation of microbial mixtures
will identify potential mechanistic relationships among mi-
crobes, microbial antigens, and host responses [41,42].
While the advances in phenotyping and genotyping ex-
periments may pave the way for the identification of
biomarkers that may be clinically actionable, there are chal-
lenges and limitations to their effective, wide-scale application.
For example, a specific challenge is the need for rapid turn-
around of next-generation sequencing results to be clinically
actionable; at present, this is not routinely available due to
the need to batch samples to reduce the costs of sequenc-
ing. Thus, while next-generation sequencing and metabolomic
approaches are the predominant technologies used in the re-
search setting, some intriguing and potentially more easily
deployed alternatives for microbiome measurement may be
more translatable. Indeed, these technologies do exist and
include approaches such as species- or bacterial group–
specific quantitative PCR [32] and microarray approaches
[33,43]. Despite the challenges to their clinical use, it is fea-
sible for advancements in microbiota science currently based
on next-generation sequencing to be optimized for real-
time use both diagnostically and prognostically in the HCT
setting.
Table 2
Early Years of Microbiota Research in Germ-Free Mice
Model system and intervention Findings References
Germ-free mice versus conventional mice Significantly milder GVHD symptoms and longer survival
after MHC-disparate allo-HCT in germ-free mice
Connell, 1965 [4]
Jones, 1971 [5]
Van Bekkum, 1961 [6]
Van Bekkum, 1977 [7]
Intact GVT and reduced GVHD after MHC-disparate allo-





Germ-free mice versus conventional mice versus mice
with consortium of colonization resistant intestinal
microflora (anaerobes)
Significantly milder GVHD symptoms and longer survival
in both germ-free and colonization resistant mice whose
microflora was predominantly anaerobic
Conventionalization of all mice after 40 days did not did
not induce GVHD in gnotobiotic mice that received
colonization resistant microflora but did in conventional
mice treated with antibiotics
Van Bekkum, 1974 [12]
Antibiotic-treated mice versus untreated mice Significantly milder GVHD in xenogeneic rat-to-mouse
HCT; GVHD histology present but less inflamed in
antibiotic-treated mice compared with conventional mice
Heit, 1973 [13]
Significantly milder GVHD symptoms and longer survival
after MHC-disparate allo-HCT in antibiotic-treated mice
Van Bekkum, 1967 [14]
Heit, 1977 [15]
Selective antibiotic decontamination of
Enterobacteriaceae versus conventional mice
Mitigation of delayed-type GVHD by selective
decontamination of Enterobacteriaceae was minor and
dependent on mouse model
Veenendaal, 1988 [16]
MHC indicates major histocompatibility.
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Open questions
● How do we design and execute microbiome studies that
permit simultaneous characterization of (1) microbes
beyond taxonomy and (2) both host impact on and host
response to the microbiome, thus informing a deeper un-
derstanding of microbiota function?
● What new technologies (eg, single cell sequencing, T cell
receptor sequencing, long-read sequencing, and ad-
vanced imaging) will emerge as new ways to measure the
Table 3
Clinical Studies of Protective Isolation with Gut Decontamination in HCT Patients
Intervention Control Outcomes (intervention versus control) References
Randomized trials
Protective isolation (LAF isolation,
skin cleansing, sterile diets) + oral
antibiotic decontamination (n = 45)
Oral antibiotic
decontamination (n = 44)
• Decreased risk of infection Buckner, 1978
[17]• Fewer patients with septicemia
• Fewer days with septicemia
• Longer time to first major infection
• Later onset GVHD (only in aplastic anemia
patients)
• No difference in survival
• Of note, adherence to oral antibiotic
decontamination was poor
LAF isolation + oral antibiotic
decontamination (n = 36)
Conventional rooms + hand
washing and mask precautions
(n = 31)




• Later onset acute GVHD
• Trend toward decreased incidence of grade II to IV
acute GVHD; not statistically significant
• Increased survival
LAF isolation + oral nonabsorbable
antibiotics + prophylactic systemic
antibiotics (n = 54)
LAF + oral nonabsorbable
antibiotics (n = 68)
• Fewer episodes of septicemia Petersen, 1986
[19]• No difference in incidence or severity of GVHD
• No difference in mortality
Conventional rooms + prophylactic
systemic antibiotics (n = 45)
Conventional rooms + prophylactic
granulocyte infusions (n = 67)




• No difference in GVHD incidence
• No difference in mortality
LAF + prophylactic systemic
antibiotics (n = 49)
Conventional rooms+ prophylactic
systemic antibiotics (n = 50)
• Decreased septicemia Petersen, 1987
[21]• Decreased major local infections (borderline
significance)
• No difference in GVHD incidence
• No difference in mortality
Conventional
rooms + ciprofloxacin + metronidazole
gut decontamination (n = 68)
Conventional rooms + ciprofloxacin
gut decontamination (n = 66)
• Decreased incidence of acute GVHD Beelen, 1999
[22]• No difference in chronic GVHD
• No difference in OS
Observational trials
LAF isolation + oral antibiotic
decontamination (n = 39)
Conventional rooms + oral
antibiotic decontamination
(n = 91)
• Decreased incidence of acute GVHD Storb, 1983
[23]• Increased long-term survival
LAF isolation + oral and topical
antibiotic decontamination (n = 26)
Conventional rooms + barrier
nursing +oral and topical antibiotic
decontamination (n = 22)
• No difference in GVHD incidence Mahmoud,
1984 [24]• No difference in mortality








• Fewer days of fever and fewer infections Schmeiser,
1988 [25]• Trend toward decreased GVHD although not
statistically significant
LAF + complete antibiotic oral
decontamination (n = 44)
LAF + selective decontamination
(n = 21)
• Fewer infections Vossen, 1990
[26]• Decreased acute and chronic GVHD incidence
• Lower combined TRM or chronic GVHD incidence
Sustained growth suppression of
anaerobic bacteria with oral
nonabsorbable and systemic
antibiotics (n = 41)
Incomplete growth suppression of
anaerobic bacteria despite oral
nonabsorbable and systemic
antibiotics (n = 153)
• Decreased incidence of acute GVHD Beelen, 1992
[27]
Protective isolation with either LAF
or HEPA filters (n = 4238)
Conventional isolation (n = 827) • No difference in acute or chronic GVHD incidence Passweg, 1998
[28]• Decreased TRM and overall mortality in the first
100 days post-transplant
Protective isolation + successful gut
decontamination with oral
nonabsorbable and systemic
antibiotics (n = 57)
Protective isolation -successful gut
decontamination despite oral
nonabsorbable and systemic
antibiotic (n = 55)
• Decreased infectious risk Vossen, 2014
[29]• Decreased incidence of acute GVHD
LAF indicates laminar air flow; OS, overall survival; TRM, transplant related mortality.
* Reverse isolation was achieved in sterile plastic isolators.
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microbiome, its structure, function and interactions with
the host; how should we apply these approaches in the
HCT setting?
● What strategies for multicenter collections of biospecimens
and clinical data best support future integrative “multi-
omic” approaches to illuminate host-microbe relationships
as they pertain to HCT outcomes?
THE MICROBIOME AS BIOMARKER
Identifying biomarkers with high prognostic and predic-
tive value is crucial for communicating risk to patients and
selecting appropriate therapeutic strategies. Thus, it is no
surprise that composition of the intestinal microbiota, which
is affected by host genetic factors, immunological factors, diet,
medications, lifestyle, and environmental exposures, has been
analyzed as a biomarker for important clinical outcomes after
HCT. During transplantation, dramatic shifts in the compo-
sition of the intestinal flora are observed [1]. These shifts in
species abundance and measures of diversity have been pro-
posed as potential biological markers associated with patient
outcomes after transplantation (Table 6) [1-3,22,27,44-49].
Biomarkers such as these may prove useful in the design of
clinical trials to identify patients at risk of certain out-
comes, as surrogate markers of clinical outcomes, or as early
predictive markers of treatment response. If a causal rela-
tionship between the microbiota and transplant outcomes can
be established, these relationships may inform the develop-
ment of microbiota-based therapeutic interventions to
improve transplant outcomes.
3-Indoxyl Sulfate as Biomarker of Intestinal Microbiota
Health
An example of a recently proposed microbiome-derived
biomarker in HCT is the small, aromatic tryptophan metabo-
lite 3-indoxyl sulfate [46,50]. Indoxyl sulfate originates from
the degradation of dietary protein-derived tryptophan to
indole by the tryptophanase of commensal intestinal bacte-
ria. After resorption of indole from the intestine, it is
metabolized to indoxyl sulfate in the liver and finally ex-
creted in the urine. Microbiota-derived indole and its
derivatives are integral to the maintenance of human mi-
crobial communities through bacteriostatic effects on Gram-
negative enteric bacteria, antifungal activities that provide
colonization resistance to Candida albicans, as well as regu-
lation of epithelial function and control of local inflammation
through induction of anti-inflammatory cytokines [51,52].
Recent studies have demonstrated that indoxyl sulfate can
serve as an important biomarker with lower urine levels being
associated with significant and clinically relevant intestinal
microbiota disruption in patients undergoing allo-HCT
[3,46,53]. In the future, metabolites such as indoxyl sulfate
may serve as a urine or serum marker for monitoring
Table 4
Sequencing Technologies Used in Microbiome Research
Method Definition References
Metagenomics The study of genes and noncoding genetic information in a mixed population of organisms to





PCR amplification of bacterial RNA/DNA from the variable regions of the 16S ribosomal RNA
gene for taxonomic profiling (the region selected is usually determined by the niche that is




High-throughput DNA sequence generation and analysis from any organism or group of
organisms via fragmentation, tagging, amplification, and massively parallel or deep
sequencing. Allows for taxonomic identification in addition to generating information about
gene presence, genetic bioregulation, and potential metabolic pathways
Loman, 2012 [33]
Metatranscriptomics High-throughput RNA sequence generation and analysis from any organism or group of
organisms via reverse transcription, tagging, amplification, and massively parallel or deep
sequencing. Provides a snapshot of which genes are being transcribed
Marchesi, 2015 [31]
Metabolomics Characterization of the collection of metabolites produced by an organism or a single tissue.
The term has been used to described characterization of the collection of metabolites
produced by a collection of organisms (ie, the microbiota), although some prefer the term
metabonomics for that definition
Marchesi, 2015 [31]




Diversity Measurement of the number of different types (taxa) of organisms and their abundance. Alpha-
diversity and beta-diversity refer to diversity within and between samples, respectively
Lozupone, 2012 [35]
Dysbiosis Perturbation of the taxonomic structure and function of the microbiota from the healthy state. This
can be associated with the development of disease
Petersen, 2014 [36]





The transfer of stool from a donor to a recipient via either endoscopy, nasogastric/duodenal tube,
capsules, or enema for the purpose of altering the intestinal microbiota of the recipient and restoring
health. Stool is obtained from healthy related or unrelated donors, and less commonly from the
intended recipient
Borody, 2013 [38]
Microbiota The entirety of microorganisms (bacteria, archaea, viruses, fungi, and other eukaryotes) within a
specific habitat
Marchesi, 2015 [31]
Microbiome Includes the biotic (microorganisms and their genomes) and abiotic (environmental) factors present
within a particular habitat. This definition is modeled after the meaning of the term “biome”. Many in
the field use the term microbiome to refer to the collection of genes and genomes within a particular
habitat, although this definition is redundant with “metagenome”
Marchesi, 2015 [31]
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microbiota perturbations in patients being treated with an-
tibiotics or in predicting the development of GVHD [46].
Open questions
● Can the composition of the intestinal microbiota serve as
a biomarker for clinical outcomes after HCT and can it be
used to guide interventions?
● Are there specific microbes that are causally associated
with positive or negative outcomes of HCT, perhaps
through their antigenic properties or through the action
of generated metabolites? If so, might there be
strain-specific differences in their capacity to induce in-
flammation or cytotoxic damage?
● How can changes in the microbiome be assayed in real
time to allow for clinical decision making?
INTERACTIONS BETWEEN THE MICROBIOME AND THE
IMMUNE SYSTEM
The Microbiome and Development of the Immune System
Proper immune reconstitution is central to successful HCT.
To better understand immune reconstitution in patients fol-
lowing HCT, it is helpful to turn to the well-studied and
analogous process of immune development in neonates. The
adaptive immune system and microbiota undergo a process
of rapid change and development over the first 3 years of
human life, and these 2 processes are intimately intercon-
nected [54]. Developmental microbiota perturbations have
been associated with short-term immune consequences early
in life, and there is a strong suggestion that these early per-
turbations may have long-term deleterious effects on immune
function as well [55-60]. As successful immune reconstitu-
tion is central to HCT efficacy in the short and long term, it
is critical to understand exactly how the microbiota impacts
that process.
Axenic or “germ-free” animal models have been an es-
sential tool in defining the importance of microbes to immune
development [61-63]. Studies in these systems have shown
that the immune system of a germ-free neonate is under-
developed [64]. Most notable are the changes observed in
mucosal immunity, particularly in the intestine, with absence
of gut-associated lymphoid tissue, including isolated lym-
phoid follicles, Peyer’s patches, and mesenteric lymph nodes
[65]. While many similarities exist between the immuno-
logic development process in infants and HCT recipients, some
differences must also be considered. Notably, the adult in-
testinal microbiome is quite divergent from the infant
microbiome, and individuals undergoing HCT have often re-
ceived antimicrobial and other pharmacological agents that
damage the microbiota composition. Thus, while the
microbiota likely plays a role in immune reconstitution post-
HCT, we must carefully consider both the similarities and
differences to the process of infant immune development as
we try to understand how the microbiota impacts both
immune reconstitution and adverse immunological post-
HCT outcomes such as GVHD.
The Microbiome and Its Role in Immune Reconstitution
Post-HCT
Impaired immune reconstitution after HCT is a signifi-
cant cause of morbidity and mortality, and has been
implicated in increased risk of infections, malignancy relapse,
and development of secondary malignancies [66-74]. Given
recent data on the interactions between the gut microbiome
and transplant outcomes discussed previously, as well as the
immune system [75-78], it is reasonable to hypothesize that
the microbiome plays a direct role in post-transplant immune
recovery. The study of post-transplant immune reconstitu-
tion now benefits from a variety of quantitative and qualitative
assays, including clinical parameters such as absolute lym-
phocyte counts, lymphocyte subsets (CD4+ and CD8+ T cells,
natural killer cells, B cells), and antibody titers, as well as more
complex functional assays and evaluations of T cell and B cell
repertoire, and next-generation sequencing approaches to
provide information on TCR diversity and specific clonotypes
over time [79]. Currently, no integrated datasets comprising
Table 6
Clinical Studies Examining the Microbiota as a Biomarker for HCT Outcomes
Microbiota Feature Association Sample
size
References
Sustained decontamination of gut anaerobes Lower risk of GVHD 194 Beelen, 1992 [27]
Decontamination of gut anaerobes Lower risk of GVHD 134 Beelen, 1999 [22]
Intestinal monodomination by Enterococcus and
Proteobacteria
Higher risk of bacteremia and intestinal GVHD 94 Taur, 2012 [44]
Intestinal monodomination, especially by Enterococcus Higher risk of bacteremia and intestinal GVHD 31 Holler, 2014 [3]
Decreased duodenal Paneth cell counts at GVHD Higher GI GVHD severity, lower GVHD treatment response,
and higher NRM
142 Levine, 2013 [45]
Low intestinal microbiota diversity Lower OS, higher TRM 80 Taur, 2014 [1]
Lower urinary 3-indoxyl sulfate Higher intestinal microbiota dysbiosis, higher risk of GVHD 31 Holler, 2014 [3]
Lower urinary 3-indoxyl sulfate Higher intestinal microbiota dysbiosis, higher TRM, lower OS 131 Weber, 2015 [46]
Higher fecal Blautia abundance Lower GVHD-related mortality, higher OS 115 Jenq, 2015 [47]
Higher abundance or presence of a cluster of bacteria
including Eubacterium limosum in fecal microbiota
Lower risk of relapse or progression of disease, higher OS 541 Peled, 2017 [2]
Higher gradient of positively to negatively correlated
organisms at neutrophil recovery
Higher risk of severe acute GVHD 66 Golob, 2017 [48]
Picobirnivirus presence Severe GI GVHD 44 Legoff, 2017 [49]
All studies are observational except Beelen, 1999 [22].
GI indicates gastrointestinal; NRM, nonrelapse mortality; OS, overall survival; TRM, transplant related mortality.
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simultaneous host and microbiome measurements are pub-
licly available for analysis. Future prospective studies will need
to integrate these areas of research to better define poten-
tial interactions between the immune system and the
microbiome in HCT, as has been done in the integrative
Human Microbiome Project for other diseases [39,40].
Potential Mechanisms of Immune Modulation by the
Microbiota That Impact GVHD and Graft-Versus-Tumor
Effect
The largest proportion of microorganisms in the body exists
in the lower intestine, and thus the intestine is believed to
be the major interface between the microbiome and adap-
tive immune system. Intestinal homeostasis is a dynamic
process that includes maintenance of bowel mucosa integ-
rity and relies heavily on the interactions between
immunologic function and the community of organisms that
make up the gut microbiota. HCT leads to dysbiosis and dis-
ruption of intestinal homeostasis as a result of the conditioning
regimen, use of broad-spectrum antibiotics, alterations in nu-
trition, and donor cell-derived immune reconstitution. There
is clinical evidence for the regulatory effect of gut microbiota
in the maintenance of intestinal homeostasis mediated pri-
marily through regulatory T cells [80-82]. For example,
emerging data suggest that alterations in the intestinal
microbiota and metabolome are associated with the inci-
dence and severity of acute GVHD (Tables 7A and 7B)
[1,3,22,26,27,29,48-50,54,76,84-96]. While the majority of the
literature has focused on changes in intestinal microbiota di-
versity, others have focused on the role of particular organisms,
such as Blautia spp. in protection from GVHD [47]. Reports of
GVHD associated with blooms of eukaryotic viruses, such a
picobirnaviruses, have also begun to emerge, suggesting a po-
tential role for the human virome as, at the very least, a marker
of this transplant complication [49]. In addition to increas-
ing GVHD risk, disruption in intestinal homeostasis and
dysbiosis is associated with increased treatment-related mor-
tality (TRM), and decreased overall survival [2,3,48].
Commensal bacteria can also play a role in tumor
immunosurveillance. Although the precise mechanisms by
which intestinal microbes can promote tumor immunity are
unknown, one hypothesis invokes antigen mimicry, as mi-
crobial proteins can bear close resemblance to tumor-
associated antigens [96],. An alternative pathway might be
through nonspecific activation of innate immune cells and
pathways. Consistent with the notion of the microbiome in-
fluencing antitumor immunity, it was recently shown that
specific members of the intestinal microbiota are associ-
ated with a decreased risk of relapse after allo-HCT [2].
Achieving a comprehensive understanding of the mecha-
nisms driving both mucosal and systemic immune modulation
by the gut microbiota may facilitate the simultaneous mit-
igation of GVHD while maintaining or improving GVT effects.
Whether particular microbiota signatures correspond to
a causal or contributing factor to the development of various
disease phenotypes remains to be elucidated, as most clin-
ical studies have established only associations, with rare
exception [22]. Specifically, analyses of alterations in intes-
tinal microbiota have focused on time-course compositional
descriptions and correlations with clinical and biological out-
comes, in particular acute GVHD. Future research will
undoubtedly bring greater focus on both intestinal and
extraintestinal microbial alterations and their mechanistic
impact on the development and severity of acute and chronic
GVHD in addition to other transplant outcomes. The exper-
imental data so far indicate that modification of the gut
ecosystem to restore intestinal homeostasis may represent
a novel approach to modulate complications of HCT. While
attempts at altering therapeutically the established intesti-
nal dysbiosis could potentially improve transplant outcomes,
we are in the beginning phases of comprehending the full
impact and the mechanistic role of microbiota in HCT, not only
for GVHD outcomes, but also for tumor relapse, infectious
complications, and long-term outcomes after HCT.
Open questions
● Can we identify specific associations among the micro-
bial taxa, antigens, or metabolites and post-HCT immune
recovery?
● Is the pretreatment microbiome (before any treatment for
the underlying disorder) prognostic of immunologic and
other outcomes post-transplant?
● What is the role of oral and skin microbiomes as well as
microbes from other organs on the incidence and severity
of acute and chronic GVHD? Is there a specific set of in-
testinal and extraintestinal (eg, ocular, skin, vaginal)
microbial taxonomic structures over time that correlate
with or are causally related to chronic GVHD and late
effects of HCT?
● How can we use interventions that modify the microbiome
to improve post-HCT outcomes, specifically mediated by
immune effects on GVHD and GVT?
● Do specific T cell responses against bacterial antigens affect
donor and recipient T cell repertoires and therefore play
a role in HCT outcomes?
● Do donor lymphocyte infusions, checkpoint inhibitors, chi-
meric antigen receptor T cell and other T cell therapies
impact the microbiome? If so, does the microbiome in any
way mediate clinical outcomes following these therapies?
THE MICROBIOME AND ITS ROLE IN INFECTION AND
IDIOPATHIC POST-HCT DISORDERS
Infection is a major cause of nonrelapse morbidity and mor-
tality after HCT, second only to GVHD. Unfortunately, other than
administering prophylactic antibiotics or antiviral agents to sus-
ceptible patients, the therapeutic approach against these
infections is largely reactive. Thus, identifying modifiable host
or microbiome features that can be manipulated to prevent
infection is a very attractive and promising proposition. The
gut microbiota plays a critical role in maintaining coloniza-
tion resistance against intestinal pathogens, and the
mechanisms that underlie this regulation are becoming in-
creasingly well understood. The composition of intestinal
microbiota is actively regulated by a number of internal and
external factors, ranging from diet to antibiotics, to the ele-
ments of the adaptive and innate immune system. An
important element of the innate immune system that shapes
the microbiota is host-derived antimicrobial peptides (AMPs).
Examples of such AMPs include Paneth cell-derived α-defensins
and REG3α, which selectively eliminate noncommensals while
preserving commensals, and thus serve as microbiome modu-
lators [97,98]. Intestinal commensal bacteria can stimulate the
gut epithelium to produce AMPs that kill pathogenic bacte-
ria [99] and fungi [51]. In GVHD, for example, Paneth cell loss
is associated with both reduced secretion of α-defensins and
intestinal dysbiosis [84,100,101]. Additionally, disruption of gut
microbial communities by antibiotics can increase suscepti-
bility to intestinal pathogens [102,103]. Microbiota disruption
that leads to gut microbial monodominance (eg, a microbiome
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Table 7
Studies of Microbiota Changes Associated with GVHD in Murine Models and Microbiota Changes Associated with GVHD in Clinical Studies
A: Studies of microbiota changes associated with GVHD in murine models
Intervention/comparison Outcome (Intervention versus control) References
Reduced-intensity allogeneic versus
syngeneic HCT
• GVHD accompanied by higher Enterobacteriacea, Bacteroides and
Enterococcus spp., and lower Lactobacilli, Clostridia, Bifidobacterium, and
Bacillus spp.
• Higher Escherichia coli associated with GVHD severity and reduced
survival
• Treatment with ciprofloxacin did not affect severity of GI GVHD
Heimesaat, 2010 [84]
MHC-disparate and MHC-matched/minor
antigen-mismatched allo-HCT ± donor T
cells
• GVHD associated with:
• Loss of intestinal Paneth cells
• Reduction in α-defensin expression
• Lower levels of Firmicutes and Bacteroidetes
• Intestinal Escherichia coli expansion and dominance
• Lower microbiota diversity
• Oral administration of the antibiotic Polymyxin B, active against E. coli:
• Decreased GVHD severity
• Decreased GVHD-related mortality
Eriguchi, 2012 [85]
MHC-disparate allo-HCT ± donor T cells • GHVD associated with:
• Loss of intestinal microbiota diversity
• Higher Lactobacillus spp. and Enterobacteriales
• Lower Clostridiales
• Administration of ampicillin before HCT:
• Increased GVHD severity and lethality
• Higher Enterococcus spp. and Enterobacteriaceae
• Lower Blautia spp. abundance
• Administration of Lactobacillus johnsonii prevented ampicillin-induced
effects
Jenq, 2012 [76]
MHC-disparate allo-HCT using T cells from
specific pathogen-free versus germ-free
donor
• T cell donor microbiota presence or absence did not alter:




MHC-disparate allo-HCT ± intestinal
helminth infection
• Infection with murine nematode Heligmosomoides polygyrus:
• Lowered GVHD severity
• Preserved GVT effect
• Increased Treg abundance and improved immune regulation
• Increased survival of GVHD mice
• Protective effects of helminthic infection dependent on TGF-β
Li, 2015 [87]
MHC-matched/minor antigen-mismatched
allo-HCT with antianaerobic antibiotics
(imipenem-cilastin or piperacillin-
tazobactam) versus antibiotics lacking in
ant-anaerobic activity (aztreonam)
• Treatment with anti-anaerobic antibiotics associated with:
• Higher mortality
• Higher severity of GI GVHD
• Increased GI inflammatory infiltration
• Higher levels of IL-23 (mediator of GVHD)
• Greater abundance of mucin-degrading Akkermansia
Shono, 2016 [88]
MHC-disparate versus syngeneic allo-HCT
1) + /- intragastric lavage of 17 butyrate-
producing strains of Clostridia spp.
2) Anti-anaerobic antibiotics ± Clostridia spp.
• Gavage with Clostridia spp. resulted in lower GVHD severity and higher
survival
• Anti-anaerobic antibiotics followed by gavage by Clostridia spp. replicated
these findings
Mathewson, 2016 [89]
MHC-disparate allo-HCT + levofloxacin
1) + /- clindamycin
2) Clindamycin ± anti-inflammatory
Clostridia spp. (AIC)
• Treatment with clindamycin decreased survival
• Clindamycin treatment + AIC increased survival
Simms-Waldrip,
2017 [90]
B: Microbiota changes associated with GVHD in clinical studies
Intervention or observational group Control Outcomes (Intervention versus control) References
Randomized trials
Ciprofloxacin with metronidazole
prophylaxis (n = 68)
Ciprofloxacin
prophylaxis (n = 66)
• Lower incidence and severity of acute GVHD Beelen, 1999 [22]





decontamination (n = 18)
• Lower incidence of acute and chronic GVHD Vossen, 1990 [26]
• Lower rate of infection
• Lower combined TRM and chronic GVHD
Sustained suppression of anaerobic
intestinal flora (n = 41)
Incomplete suppression of
anaerobic intestinal
flora (n = 153)
• Lower incidence of acute GVHD Beelen, 1992 [27]
Acute GVHD (n = 8) No GVHD (n = 10) • Lower intestinal microbiota diversity Jenq, 2012 [75]
• Higher Lactobacillales
• Lower Clostridiales
(Continued on next page)
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Table 7
(continued)
B: Microbiota changes associated with GVHD in clinical studies




decontamination (n = 55)
• Lower incidence of acute GVHD Vossen,
2014 [29]• Lower infectious risk
Lowest GI microbial diversity at
engraftment (n = 34)
Intermediate or high GI
microbial diversity at
engraftment (n = 20 intermediate,
n = 26 high)
• Lower OS Taur, 2014 [1]
• Higher TRM, specifically mortality related to
GVHD
or infection
Colonized with Candida in the
intestine (n = 54)
Not colonized with Candida in
the intestine (n = 99)
• Higher incidence of acute GVHD van der Velden,
2013 [91]
Acute GI GVHD (n = 8) No GI GVHD (n = 23) • On the day of transplant:
• Higher Enterococcus spp.
• Lower Clostridia spp. and Eubacterium rectale
Holler, 2014 [3]
Acute GVHD (n = 5) No GVHD (n = 5) • Before transplant:
• Lower diversity
• Lower Bacteroides and Parabacteroides spp.
• Lower proprionate and SCFAs
• Between day 0 and day+35:
• Higher Enterococcus spp.
• Lower Faecalibacterium spp
• Over all time points:
• Lower Bacteroidetes
Biagi, 2015 [92]
Lower microbial diversity (n = 32),
lower Blautia abundance (n = 58)
Higher microbial diversity
(n = 32), higher Blautia
abundance (n = 57)
• Lower microbiota diversity and lower abundance
of Blautia spp. associated with higher GVHD-
related mortality
• Higher Blautia abundance associated with higher
OS
Jenq, 2015 [48]
Colonized with ARB pretransplant
(n = 33)
Non-ARB colonized (n = 74) • Higher incidence of acute GVHD and acute GI
GVHD






Treatment of febrile neutropenia
with antibiotics effective against
anaerobic bacteria:
• Imipenem-cilastin (n = 148) or
• Piperacillin-tazobactam (n = 300)
Treatment with antibiotics less
effective or ineffective against
anaerobic bacteria:
• Cefepime (n = 152)
• Aztreonam (n = 64)
• Higher risk of 5-year GVHD-related mortality
• No difference in OS
Shono,
2016 [88]
Acute GVHD (n = 6) No GVHD (n = 9) • GVHD associated with:
• Higher cumulative antibiotic exposure and
antianaerobic antibiotic exposure,
specifically to clindamycin
• Higher Enterobacteriacea, Enterococcus spp.,
and Neisseriaceae
• Lower anti-inflammatory Clostridia,
Bacteroidetes, and Actinobacteria




or treatment (n = 239)
No pretransplant antibiotics
(n = 261)
• Higher incidence and severity of acute GVHD and
GI GVHD





(n = 297) or no antibiotics
(n = 88)
• Lower urinary indoxyl sulfate
• Lower Clostridiales
• Higher acute and/or chronic GVHD-related
mortality





diversity (n = 18)
Preconditioning intermediate
(n = 48) and high diversity
(n = 41)
• Before conditioning:
• No difference in incidence of acute GVHD or
GI GVHD
• Higher Firmicutes, and a nonsignificant
trend toward lower Bacteroidetes in those
who later developed acute GVHD
• No difference in OS, relapse, or NRM
Doki, 2017 [95]
(Continued on next page)
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dominated by Enterobacteriaceae or Enterococcus spp.) pre-
cedes and significantly increases the risk of bacteremia (with
Enterobacteriaceae or Enterococcus spp.) in HCT patients [44].
In preclinical models, a 1- to 2-log fold reduction in bacterial
[104] or fungal [51] gut colonization levels is sufficient to sig-
nificantly decrease pathogen dissemination and mortality.
Similarly, specific gut commensals can provide resistance to
Clostridium difficile infection [102]. Thus, efforts targeted at pro-
tecting the commensal microbiome may protect against
intestinal pathogens and infections.
The role of microbiome-host crosstalk and whether spe-
cific molecules or pathways in this cross-talk can be
manipulated toward therapeutic benefit remains an active
field of investigation. Oral administration of synthetic AMPs
may restore gut ecology and shape the host immune system
to decrease the risk of infection as well as reducing GVHD,
while preserving the graft-versus-leukemia effect. As with
nearly all antibacterial agents known to date, resistance to
specific AMPs has been described [105]. An alternative
strategy that leverages a larger spectrum of AMPs and thus
protects against rapid acquisition of resistance might be stim-
ulation of the intrinsic production of AMPs. Although
augmenting innate cellular function or mucosal integrity is
difficult, it may be possible in the future through modula-
tion of gut microbiota or directly inducing gut mucosal
immune effectors to tip the balance back toward gut homeo-
stasis, restore colonization resistance, and reduce the risk of
severe infections.
In addition to efforts focused on microbiome modulation
to protect against bacterial infections, the importance of
microbiota in the control of viral infections and host immune
responses has been increasingly recognized. Studies specific
to HCT patients or to viruses commonly encountered in HCT
(ie, cytomegalovirus, Epstein-Barr virus, adenovirus, and re-
spiratory syncytial virus) are still very limited. The interactions
among microbiota, host immune response, and viral infec-
tions are complex and multidirectional: for example, the
microbiome may influence viral-specific CD8 T cell memory
[106], which can modulate clinical symptoms, severity, and
clearance of viral infections [107], or in reverse, a viral in-
fection may result in a change in the microbiome through host-
immune responses and changes in cytokines, including
interferon [108]. Pathogenic or nonpathogenic viruses within
the respiratory tract [109], skin, or gut [110] may also inter-
act with the bacterial microbiome in what has been termed
“trans-kingdom interactions” [111]. Host immune responses
to prophylactic vaccines or antiviral drugs can also be influ-
enced by the status of the microbiota, and this may impact
future decision making around routine decisions such as the
schedule for immunizations post-HCT [112].
A proportion of non–relapse-related mortality in HCT pa-
tients results from non-GVHD and noninfectious complications
for which clinicians are unable to ascribe a clear etiology.
These so-called idiopathic disorders may be related to an un-
derlying microbiome dysbiosis or a potential infectious trigger
that sparks a self-perpetuating inflammatory cascade (ie, a
hit-and-run phenomenon) [113,114]. The application of next-
generation sequencing methods and ultrasensitive molecular
methods for both unbiased and candidate-base pathogen de-
tection have illuminated several of these “mystery” cases
[113,115],. However, recurrent and abundant candidate patho-
gens have not yet been identified for highly morbid diseases
such as the idiopathic pneumonia syndrome. While the ev-
idence is still preliminary in most cases, it is proposed that
the microbiome or novel opportunistic pathobionts may con-
tribute to these disease phenotypes on occasion.
Table 7
(continued)
B: Microbiota changes associated with GVHD in clinical studies
Intervention or observational group Control Outcomes (Intervention versus control) References
Severe acute GI GVHD (n = 14) Nonsevere acute GI GVHD or
no GVHD (n = 52)
• At the time of engraftment:
• Lower intestinal microbiota diversity
• Higher oral Actinobacteria and Firmicutes
• Lower Lachnospiraceae
• Higher gradient of positively to negatively
correlated organisms
Golob, 2017 [49]
Acute GI GVHD (n = 26) No GI GVHD (n = 18) • Longitudinal microbiome sampling:
• Picobirnaviruses predictive of severe enteric
GVHD occurrence
• Higher picobirnaviruses before or within a
week after transplant
• Increased rate of detection and number of
sequences of persistent DNA viruses over
time
• No difference in overall richness
• Reduced microbial phage richness over time
Legoff 2017 [50]
Acute GVHD (n = 34)




• Lower recipient intestinal microbiota
diversity compared with HLA-matched
sibling donors
• High donor intestinal microbiota diversity is
associated with lower acute GVHD incidence
in recipients
• Low preconditioning intestinal microbiota
diversity (in recipients) was not associated
with higher risk of acute GVHD
• Lower recipient diversity associated with
lower OS
Liu, 2017 [96]
OS indicates overall survival; TRM, transplant related mortality; SCFA, short-chain fatty acids; ARB, antibiotic-resistant bacteria; NRM, nonrelapse mortality.
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The role of the microbiome in modifying the incidence and
clinical outcomes of infection and idiopathic disorders in HCT
patients is becoming increasingly recognized. To date, most
research has focused on the bacterial contribution to these
disorders, but increasingly, there is an appreciation of the con-
tribution of viruses to these disorders and to the delicate
balance of the microbiome. Both host and microbial factors
participate in a complicated interplay to maintain homeo-
stasis, and we are just now starting to understand the detailed
elements in this complicated interaction. Little is known about
the fungal contribution to both the healthy and diseased HCT
microbiome, although we anticipate this will be an area of
active and productive research in the future.
Open Questions
• What is the composition of the human “virome” and
“mycobiome” in HCT patients—and how do interactions
among viruses, fungi, bacteria, and the host impact HCT
outcomes?
• Do antimicrobial prophylaxis strategies adversely impact
the microbiota and render HCT recipients susceptible to
opportunistic infections beyond C. difficile?
• Might microbiome-targeted therapeutics, aimed at pro-
tecting against loss of diversity in the microbiome, decrease
the rate of infectious complications such as enteric Gram-
negative and Gram-positive bacteremia believed to
originate from the intestinal microbiome?
• Which of the idiopathic complications of HCT are related
to either infections or microbial dysbiosis? In cases where
the offending organism acts through a hit-and-run type
of mechanism, how might we identify these etiologies
using existing technologies and sampling strategies?
METHODS FOR MICROBIOTA MODIFICATION
A clear rationale exists for targeting the microbiome with
the eventual intention of both fine-tuning the immune system
(balancing GVHD and GVT, for example) and decreasing the
risk of downstream infectious complications of HCT. Several
interventional studies are ongoing that will alter microbiota
by means of diet and prebiotics, antibiotics, probiotics, mi-
crobial metabolites, and fecal microbial transplantation
(Table 8). Subsequently we discuss several clinical microbiome
manipulation strategies and the implications of their use in
future studies.
Antibiotics
Over the past 10 years, metagenomic and other culture-
independent microbiota analyses have demonstrated the
important role of the microbiome in health and disease [116].
Table 8
Clinical Trials with Microbiota-Based Interventions in HCT Patients
Name Comparison Outcomes Study type Clinical Trials.gov ID Status
Dietary interventions
Comparing two diets in patients undergoing
HSCT or remission induction chemo for
acute leukemia and MDS
Standard hospital neutropenic
diet versus diet inclusive of







Gluten-free diet in preventing GVHD in
patients undergoing HCT
Gluten-free diet GVHD Single arm NCT03102060 Recruiting
Randomized, prospective, multicenter study
to compare enteral nutrition to parenteral
nutrition as feeding support in patients







Donor human milk in young children










Prebiotic and probiotic interventions
Modification of the intestinal microbiome by
diet intervention to mitigate acute GVHD





NCT02763033 Not yet open




Single arm NCT02805075 Recruitment
completed
Lactobacillus rhamnosus GG in reducing









Fecal microbiota transplantation (FMT)
Auto-FMT for prophylaxis of CDI in
recipients of Allo-HCT
Auto-FMT versus control CDI Randomized
open label
NCT02269150 Recruiting
Fecal transplant for steroid-resistant and
steroid-dependent gut acute GVHD
Fecal microbiota transplant Safety, GVHD Single arm NCT03214289 Recruiting
Antibiotic interventions
Choosing the best antibiotic to protect











Gut decontamination in pediatric allo-HCT Oral Vancomycin-Polymixin B







FOS indicates fructo-oligosaccharides; CDI, Clostridium difficile infection.
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Patients undergoing HCT represent a natural group for this
line of research for the reasons that they are (1) uniquely
prone to perturbations in the normal microbiome as a result
of toxicity from conditioning regimens, impaired diet, and an-
timicrobial exposure given for treatment and prophylaxis:;
(2) their propensity for infectious and immune-mediated mor-
bidity and mortality; (3) their prolonged peritransplant
hospitalization that facilitates convenient sampling; and (4)
the availability of long-term outcomes that are universally
gathered from transplant recipients. Early studies of prophy-
lactic antibiotics in HCT demonstrated reductions in both
infections and GVHD after suppression of the microbial flora
[26]. Although the use of broad-spectrum antibiotics has led
to dramatic improvement in infection-related TRM, antibi-
otics result in substantial microbiota disruption [53].
Importantly, the type of antibiotic therapy may determine the
composition of intestinal microbiota and the extent of
microbiome disruption. For example, antibiotics with anaer-
obic activity are associated with higher rates of GVHD-
related mortality [87]. These new insights, which suggest an
unfavorable impact of broad-spectrum antibiotics on intes-
tinal microbiota and patient outcomes after HCT, raise the
question of how we might preserve the protective effects of
“healthy” commensal organisms without compromising treat-
ment efficacy. In addition to the type of antibiotic, timing of
treatment also appears to influence microbial diversity and
may impact patient outcomes. Patients starting antibiotics
before their day of transplantation showed significantly more
microbiome disruption and had a higher TRM than did those
who began antibiotics on or following day 0 or who did not
receive antibiotics [53]. Collectively, these studies support an
argument for more selective use of broad-spectrum antibi-
otics along with early de-escalation strategies. Such strategies
would preserve the microbiome but still ensure adequate pre-
vention and treatment of bacterial infections. Further, the
benefit of gut decontamination and prophylactic antibiotics
should be examined through well-designed prospective trials.
Definitive support for or against these practices will only come
through the conduct of multicenter prospective trials de-
signed to assess the short-term risk of bacterial infections
during neutropenia with long-term endpoints (GVHD,
immune reconstitution, and microbial resistance) that may
be affected by disruption of microbiome diversity.
Open question(s)
● How do we balance adequate prevention and treatment
of bacterial infections with preservation of the microbiome
in HCT recipients?
● How can we incorporate microbiota stewardship prac-
tices in addition to antibiotic stewardship practices in our
care of HCT recipients?
Diet, Prebiotics, Probiotics, and Fecal Microbiota
Transplantation
Ingested food contaminated by microbes has long been
recognized as a potential source of bloodstream infection
during chemotherapy-induced neutropenia with attendant
gastrointestinal mucosal damage. The germ-free “sterile” diet
was conceived in the 1960s as a way to reduce ingestion of
potentially harmful microbes, but this was not palatable [117].
A “cooked-food” diet alternative, which eliminated raw foods
with high bacterial counts, was shown in a randomized trial
to have a similar effect on bacterial stool cultures as the germ-
free diet, but it was also limited by patient dissatisfaction
[117]. To expand and improve food palatability, Pizzo et al.
[118] cultured commercially available foods and identified
low-microbial foods that were deemed suitable for a neu-
tropenic diet. The composition of neutropenic diets vary from
center to center but, in general, consist of cooked and canned
food products and exclude raw meat, fresh fruits, juices and
vegetables, raw eggs, and unpasteurized dairy products
[117,119]. Despite limited evidence to support the merits of
a neutropenic diet in HCT recipients as illustrated in Table 9
[120,121], dietary restriction of fresh fruits and vegetables con-
tinues to be standard practice for neutropenic patients in some
centers, which likely has an impact on the amount of fiber
that is consumed by HCT patients [122]. In the early post-
transplant period, nutritional oral intake often declines to the
point of necessitating nutritional supplementation. Retro-
spective comparisons of parenteral and enteral nutrition have
suggested a benefit to the enteral route [123,124]. This may
be due to enteral nutrition maintaining digestive function and
the mucosal barrier, thus preventing bacterial translocation
[125]. An ongoing trial is currently evaluating enteral versus
parenteral nutrition [126].
Specific elements of diet, called prebiotics, are particu-
larly influential in the structure and function of the microbiota.
The term “prebiotic” is traditionally applied to indigestible
carbohydrates that are metabolized by gut bacteria to produce
short-chain fatty acids; recently the term is being redefined
to refer to any substrate that is selectively utilized by host
microorganisms and that confers a health benefit [127]. Apart
from a single retrospective study, little is known about how
prebiotics affect transplant outcomes such as GVHD [128,129].
However, studies in patients with inflammatory bowel disease
treated with prebiotics such as inulin and fructo-
oligosaccharides (inulin-type fructans) have demonstrated that
Table 9
Clinical Trials Investigating the Efficacy of a Neutropenic Diet in HCT Patients
Intervention Control Outcomes (Intervention versus control) References
Randomized controlled, prospective trial
Unrestricted diet (n = 21) Neutropenic diet (n = 25) • No difference in infectious outcomes Lassiter, 2015 [120]
• No difference in nutritional status
Retrospective observational study
General hospital diet (n = 363) Neutropenic diet (n = 363) • Fewer microbiologically confirmed infections in those
receiving a general diet
Trifilio, 2012 [121]
• No difference in the incidence of microbiologically
confirmed infections during neutropenia
• Higher rate of infections after resolution of neutropenia in
those receiving a neutropenic diet
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these agents increase microbiota diversity and are associ-
ated with a corresponding decrease in disease markers and
activity [130,131],. Such studies provide a compelling ratio-
nale for studies of prebiotics in the HCT setting.
Probiotics are live microorganisms given to improve health
and have long been used as part of traditional diets through
the ingestion of fermented foods. Encapsulated prepara-
tions of 1 or more isolated live organisms have been used in
attempts to treat a wide variety of gastrointestinal ill-
nesses, including infectious diarrhea or gastroenteritis [132],
and inflammatory bowel disease [89,133]. Some of these
studies have shown evidence of efficacy, most likely medi-
ated through direct antimicrobial effects, stimulation of
immune responses that lead to upregulation of anti-
inflammatory cytokines and IgA, and promotion of intestinal
barrier function [134,135]. To date, probiotics in the HCT
setting have been limited to preclinical models and small pilot
trials (Tables 10A and 10B) [88,89,136-139]. Of course, concern
exists for the potential infectious complications associated
with administration of live microbial organisms in high dose
[140]. Indeed, case reports of bacteremia following inges-
tion of probiotics suggest the importance of exercising caution
and judgment in the use of live bacterial therapies [141].
Further clinical studies are needed to fully determine the
safety and efficacy of probiotics in patients undergoing HCT.
Finally, fecal microbiota transplantation (FMT) is yet
another intervention that could be employed to preserve or
restore the gastrointestinal microbiota in patients undergo-
ing HCT. Pioneering physicians performed FMT in non-HCT
patients with recurrent or refractory Clostridium difficile in-
fection (CDI) and demonstrated efficacy in up to 90% of treated
patients [142,143]. Literature on FMT in HCT patients is still
scant; however, the limited data to date appear encourag-
ing, with a total of 25 reported HCT patients having undergone
FMT without known complications (Tables 11A-C) [144-151].
Highlighting the need for a cautious approach in HCT popu-
lations, case reports in non-HCT patients with CDI have
documented infectious complications following FMT includ-
ing norovirus infection and sepsis as a result of presumed
bacterial translocation [152,153]. Taken together, while limited
published experience suggests that FMT can be used in
immunocompromised patients with CDI [154], prospective
trials evaluating safety and efficacy in HCT recipients are
needed.
Undeniably, the field of FMT is rapidly growing, yet several
questions remain including what guidelines the field should
adopt for identification of the best FMT donors and
appropriate donor stool screening before FMT in
immunocompromised patients. Autologous FMT donation may
have an advantage of simple traceability of the preparation
and control of the inoculum during donor procedures, as well
as reducing the risk of potential transmission of diseases origi-
nating from the microbiota of an external donor. The
opportunity to obtain a “premorbid/baseline” stool may not
always be feasible for autologous FMT, and for this reason
several investigators are using third-party FMT obtained from
healthy donors [155]. Case reports have explored the role of
FMT for the treatment of noninfectious complications. Finally,
it is interesting to speculate about the role of the stem cell
donor’s microbiota [85,95], or the patient’s cohabitating family
members [156] from whom the microbiota may potentially
reconstitute after transplant-induced dysbiosis.
Open questions
● What is the impact of neutropenic dietary restriction and
use of parenteral nutrition on long-term outcomes
post-HCT?
● How might the screening protocol for FMT donors to HCT
patients differ than standard screening protocols used for
less immunocompromised patients?
● Can targeting of specific microbes or microbial path-
ways result in modification of microbe-disease
associations?
● Is there a role for genetically modified bacteria in the post-
HCT setting? How might this tool be safely and effectively
leveraged?
● Are there novel bacterial natural products (small mol-
ecules, proteins, glycolipids, sugars) that can be
investigated for salutary drug-like effects in the HCT patient
population?
● Might we create a defined microbial consortium as the
next-generation microbial therapeutic to supplant FMT in
the HCT recipient population?
● How stable are microbial populations and microbial
genomes over time? How does horizontal gene transfer
affect the medium- and long-term safety and efficacy of
potential novel bacterial therapies?
Table 10
Probiotics and the Microbiome in Murine Models of HCT and Probiotics and the Microbiome in Clinical Studies of HCT Patients
A: Probiotics and the microbiome in murine models of HCT
Treatment Control Outcomes References
Lactobacillus rhamnosus GG Ciprofloxacin • Lower mortality Gerbitz, 2004 [136]
• Lower GVHD incidence
17 butyrate-producing Clostridia spp. strains Phosphate-buffered saline • Lower GVHD severity Mathewson, 2016 [88]
Anti-inflammatory Clostridia spp. Phosphate-buffered saline • Higher survival Simms-Waldrip, 2017 [89]
B: Probiotics and the microbiome in clinical studies of HCT patients
Trial design Probiotic, dose Outcomes References
Observational Self-reported yogurt intake, average of 150 g/
day (n = 41)
• Higher yogurt intake associated with more rapid
neutrophil engraftment
Tavil, 2012 [137]
Single-arm Lactobacillus plantarum, 1 × 1013 CFU/kg/day (n = 30) • 97% of the children received at least half of the
probiotic doses
Ladas, 2016 [138]
• No incidence of Lactobacillus bacteremia reported
Randomized Lactobacillus rhamnosus GG, 1 × 109/day (probiotic
group, n = 20; control group, n = 11)
• No difference in gut microbiota diversity Gorshein, 2017 [139]
• No difference in GVHD incidence
CFU, colony-forming units.
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MAXIMIZING THE OPPORTUNITY FOR IMPACT
Identifying associations between the microbiome and clin-
ical phenotypes is critically important. With the advent of
technologies such as metagenomic sequencing, metabolomics,
and improved tools for studying human immunology, it is be-
coming increasingly affordable and feasible to perform
longitudinal molecular characterization of patients follow-
ing HCT. As we transition toward an increased reliance on
human samples for the generation and querying of biolog-
ical hypotheses, it is important that the same rigor used in
carefully controlled in vitro or animal experiments be applied
in the clinical setting. This is particularly important in light
of the sometimes conflicting results seen between preclini-
cal and clinical studies, possibly as a result of microbiota
variability between animal strains or differences in practice
between centers, but also potentially as a result of variation
in sample management. Samples must be collected, stored,
and processed in a reproducible manner to avoid the unin-
tended introduction of bias in the results [157]. This is of
utmost importance when studying low-biomass or low-
microbial-burden samples, where the chance introduction of
ambient microorganisms through handling or processing may
confound the ability to draw robust, reproducible, and gen-
eralizable conclusions. Similar to standard sample collection
and data generation practices, strict procedures for manage-
ment of data generated through high-throughput techniques
will ensure data quality and accuracy critical to reliable in-
terpretation and analysis. For example, current efforts to
understand the microbiome and its impact on transplant out-
comes are often limited by incomplete information on
antibiotic exposure and diet. The bone and marrow trans-
plant community has a strong track record of collecting
detailed clinical data regarding GVHD and immunosuppres-
sive medication administration. This same rigor needs to be
applied to infection reporting and antimicrobial exposure to
draw meaningful conclusions regarding microbiome find-
ings. To this end, the Center for International Blood and
Marrow Transplant Research currently has a working group
tasked with the development of reporting standards for in-
fectious disease endpoints.
As clinical infectious data collection strategies improve,
inclusion of patient-reported outcomes (PROs) should also
be prioritized in microbiome-oriented studies. PROs provide
greater accuracy of treatment-related symptoms than clini-
cian report [158], and given the role that the microbiome likely
plays in mediating symptoms such as diarrhea, constipa-
tion, flatus, and abdominal discomfort, inclusion of PROs will
be critical in studying the impact of microbiome-modifying
therapies. Specifically, validated instruments of physical func-
tion and health-related quality of life are available and include
patient-reported measures of gastrointestinal symptoms, with
domains of severity, frequency, and interference related to
Table 11
A. Fecal Microbiota Transplantation in Auto- and Allo-HCT Patients with Recurrent CDI, Fecal Microbiota transplantation in Allo-HCT Patients with GVHD,
and Fecal Microbiota Transplantation in Allo-HCT Patients with antibiotic-resistant bacteria
A: Fecal microbiota transplantation in auto- and allo-HCT patients with recurrent CDI
Patient population Total
patients
Route Donor type Outcomes Adverse events References
21-year-old woman;
allo-HCT








Resolution of CDI None de Castro, 2015
[145]




First FMT resulted in resolution
of CDI. Recurrence in 6 months.
Second FMT performed at 6
months resulted in resolution




Allo-HCT patients 7 NJ tube or
colonoscopy
Anonymous Resolution of CDI in 6 patients;
1 patient recurred at day +156
post- FMT after receiving
antibiotics. Repeat FMT with




Auto- and allo-HCT patients 8 Oral capsules Anonymous No recurrence of disease in 7
patients; 1 had recurrence of
CDI day +179 after FMT
None Moss, 2017
[148]
B: Fecal microbiota transplantation in allo-HCT patients with GVHD
Steroid-resistant GI GVHD 4 ND tube Related Resolution of diarrhea in 3




Steroid-refractory GI GVHD 3 Colonoscopy Related or
anonymous
Resolution of diarrhea in 2
patients, improvement in GI
GVHD in third patient
None Spindelboeck,
2017 [150]
C: Fecal microbiota transplantation in allo-HCT patients with antibiotic-resistant bacteria
Hematologic disorders
+ ARB colonized
20 (8 HCT) ND tube Anonymous • 75% of patients (60% of
FMTs) achieved complete
ARB decolonization at 1
month
• Vomiting (n = 1) Bilinski, 2017
[151]• Transient, grade 1
diarrhea within 3
days (n = 25)
• 93% of FMTs achieved
complete ARB
decolonization at 6 months
• Abdominal pain
(n = 2)
• Ileus (n = 2)
CDI indicates Clostridium difficile infection; NG, nasogastric; NJ, nasojejunal; ND, nasoduodenal; ARB, antibiotic-resistant bacteria.
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these symptoms contained within the NCI PRO–common
terminology criteria for adverse events (http://healthcare
delivery.cancer.gov/pro-ctcae). The successful incorpora-
tion of PROs will require (1) the development of a scalable
infrastructure for participating sites; (2) consensus choice of
relevant measures [159]; 3) collection time points so that PROs
can be appropriately linked to clinical data consistently across
research studies and clinical practice; and (4) application of
statistically sound approaches to handle missing data is of
paramount importance.
It is expected that the collection of high-quality high-
resolution molecular, clinical, and patient-reported symptom
data will hasten the identification of potentially relevant
and useful molecular biomarkers as well as associations
between microbiome alterations or specific microbes and
clinically relevant outcomes. We anticipate that “big-data”
approaches, including clinical-informatics efforts that extract
information from the electronic medical record, will be a
key part of this effort. As more and more data are collected,
it will be increasingly important to leverage machine-
learning approaches to data interpretation and analysis, as
is already being done in the field of cancer genomics and
beyond.
Perhaps most importantly, we must not lose sight of the
importance of moving “beyond association” in study design.
Strategies to model the hypothesized interactions between
the microbiome and host, both in vitro and in vivo in models
ranging from cell lines to small and large animal models, will
allow for carefully controlled experiments to be carried out—
something that is of course difficult or challenged by ethical
considerations in patient studies. Last, whenever possible, it
is critical that well designed and thoughtfully targeted
interventional studies of microbiome modification be per-
formed in multicenter settings. This will provide the highest
level of prospective data to help guide clinical practice, and
the multicenter nature of these studies will ensure the highest
level of generalizability. When these studies are done, ad-
hering to rigorous standards of biospecimen collection, clinical
data collection, and PRO data collection will allow for the ac-
curate measurement of the consequences of the tested
interventions. This will shed light on potential mechanisms
of action of these interventions, and will inform the next it-
eration of interventions (Figure 1).
Open Questions
● How can we facilitate more universal sample collection
and support multi-institutional studies of the microbiome
to improve the generalizability of findings?
● How do we identify and implement standardized methods
for sample and data collection that can be used for mul-
ticenter prospective clinical trials that study the
microbiome in HCT patients?
● How can we best collect information about infections and
antimicrobial medication use in both the clinical trial
setting and for registry purposes?
● What are the critical clinical data that need to be collect-
ed for meaningful analysis of microbiome studies in HCT?
● How can we hasten the design and execution of
microbiome-targeted interventional clinical trials? What
funding sources exist to support these critically impor-
tant efforts, given the relative paucity of classical industry
partners in this space?
FUTURE DIRECTIONS
While the importance of the microbiome in immunologi-
cal development, protection against infections, and patient
symptoms has been investigated in the past decades, much
remains to be understood on the importance and relevance
of the contribution of the stability, the resilience and the re-
dundancy of the microbial composition after transplantation.
The field has come a long way from the earliest days of
microbiome research, now nearly a half a century ago. There
has been an explosion in the number of high-throughput tools
for microbiome measurement and an increasing number of
single-institution biospecimen collections. These tools and
resources have facilitated the testing of only a limited number
of translationally important hypotheses. The taxonomic
Figure 1. Structuring the design of future interventions aimed at establishing microbe-host disease causality.
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diversity of the microbiome has been shown to be a poten-
tial biomarker of HCT outcomes, ranging from overall survival
to relapse. These early, single-institution findings are cer-
tainly compelling, and warrant further investigation.
Interactions between the microbiome and immune system
have been described for decades; deep immunophenotyping
tools such as TCR sequencing and high-dimensional mass
cytometry are now facilitating investigating the temporal re-
lationships between the microbiome and immune system
during immune reconstitution. Early data suggest a poten-
tial role for the microbiome in improving post-transplant
immune reconstitution and helping to achieve the elusive goal
of effective GVT without GVHD. A growing set of tools for
microbiome manipulation using diet, prebiotics, probiotics,
and even FMT are being tested rigorously, both in preclini-
cal models and in humans. It is anticipated that larger
randomized multi-institutional studies of these approaches
and their efficacy will be initiated. Beyond GVHD, the clear
role of the microbiome in mediating risk of infection and
perhaps idiopathic disorders also poses an exciting oppor-
tunity for investigation, and the potential to improve non–
relapse-, non–GVHD-related morbidity and mortality. To
maximize the impact of microbiome-focused investigation,
there are many targets that represent low-hanging fruit: im-
proving infection and antibiotic-related data collection,
incorporating PROs, and the application of newer methods
such as shotgun sequencing, metabolomics, metaproteomics,
advanced microscopy, and beyond, that will allow us to extend
our investigational reach beyond the taxonomic realm. A more
functional characterization of how these communities are
structured, how they interact and what they do will un-
doubtedly inform progress in developing precision
microbiome diagnostic and therapeutic strategies. Ad-
vances in technology have revealed many opportunities to
better understand the mechanisms that underlie microbiome-
host interactions. For example, recent studies have brought
to the fore the role of metabolomes and host genes that are
critical [88], yet, there have been so far no corresponding
studies on the RNA transcripts (metatranscriptomics) and pro-
teins produced by the microbes in these processes in HCT
patients. The abundance and transcript levels of genes en-
coding microbial resistance to antibiotics, drug metabolism,
and resistance to host mediated immune responses, for
example, could shed light on better exploitation of the
microbiome in HCT. Advances in bioengineering have re-
sulted in the ability to generate microbes with specific,
salutary effects. For example, oral administration of com-
mensal bacteria genetically engineered to regulate endogenous
or recombinant gene expression to alter their metabolic ability
could hold great promise for restoring intestinal homeosta-
sis and modulating host immune systems [160]. New
technologies are rapidly being developed and applied; thus,
in the coming years research will better define the role of
microbiome on GVHD, GVT, infectious complications, and
transplant outcomes. As this happens, we hope that careful-
ly considered and planned investigations ranging from basic
microbiology to immunology to large-scale, randomized-
controlled interventional clinical trials will together result in
improved outcomes for HCT and related patient popula-
tions. Simultaneously, we anticipate that such efforts will
result in an improved understanding of the basic biological
underpinnings of microbial bioregulation, microbiome com-
munity interactions, and human immunology. Vast
opportunities exist for both scientific and translational ad-
vances in the realm of microbiome sciences. To capitalize
quickly on these prospects for maximum impact, we propose
10 areas of focus (Table 1) that may have the greatest promise
for breakthrough discoveries regarding the dynamic and
complex microbiota-host relationship in patients undergo-
ing HCT.
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